PriceTargets.com logo

Cyclo Therapeutics - CYTH Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.95
  • Forecasted Upside: 34.03%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.71 As of 11/20/2024 01:00 AM ET
▲ +0.03 (4.42%)

This chart shows the closing price for CYTH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cyclo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYTH

Analyst Price Target is $0.95
▲ +34.03% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cyclo Therapeutics in the last 3 months. The average price target is $0.95, with a high forecast of $0.95 and a low forecast of $0.95. The average price target represents a 34.03% upside from the last price of $0.71.

This chart shows the closing price for CYTH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Cyclo Therapeutics. This rating has held steady since August 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/27/2024Maxim GroupReiterated RatingBuy ➝ Hold
8/26/2024Ascendiant Capital MarketsLower TargetBuy ➝ Buy$2.60 ➝ $0.95
8/23/2024HC WainwrightReiterated RatingBuy ➝ Neutral$3.00 ➝ $0.95
8/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
5/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
5/1/2024HC WainwrightInitiated CoverageBuy$3.00
4/22/2024Ascendiant Capital MarketsInitiated CoverageBuy$2.60
9/27/2023Maxim GroupUpgradeHold ➝ Buy$4.00
3/20/2023Maxim GroupDowngradeBuy ➝ Hold
10/8/2021Maxim GroupInitiated CoverageBuy$16.00
2/10/2021Maxim GroupBoost TargetPositive ➝ Buy$12.00 ➝ $25.00
12/17/2020Maxim GroupInitiated CoverageBuy$12.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Cyclo Therapeutics logo
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
Read More

Today's Range

Now: $0.71
Low: $0.69
High: $0.71

50 Day Range

MA: $0.72
Low: $0.61
High: $0.81

52 Week Range

Now: $0.71
Low: $0.59
High: $2.12

Volume

7,828 shs

Average Volume

68,337 shs

Market Capitalization

$20.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cyclo Therapeutics?

The following equities research analysts have issued stock ratings on Cyclo Therapeutics in the last year: Ascendiant Capital Markets, HC Wainwright, and Maxim Group.
View the latest analyst ratings for CYTH.

What is the current price target for Cyclo Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Cyclo Therapeutics in the last year. Their average twelve-month price target is $0.95, suggesting a possible upside of 34.0%. Ascendiant Capital Markets has the highest price target set, predicting CYTH will reach $0.95 in the next twelve months. Ascendiant Capital Markets has the lowest price target set, forecasting a price of $0.95 for Cyclo Therapeutics in the next year.
View the latest price targets for CYTH.

What is the current consensus analyst rating for Cyclo Therapeutics?

Cyclo Therapeutics currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CYTH, but not buy more shares or sell existing shares.
View the latest ratings for CYTH.

What other companies compete with Cyclo Therapeutics?

Other companies that are similar to Cyclo Therapeutics include PMV Pharmaceuticals, Quince Therapeutics, CASI Pharmaceuticals, I-Mab and Clearside Biomedical. Learn More about companies similar to Cyclo Therapeutics.

How do I contact Cyclo Therapeutics' investor relations team?

Cyclo Therapeutics' physical mailing address is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. The company's listed phone number is (386) 418-8060 and its investor relations email address is [email protected]. The official website for Cyclo Therapeutics is www.ctd-holdings.com. Learn More about contacing Cyclo Therapeutics investor relations.